Daily Stock Analysis, CTSO, Cytosorbents Corp, priceseries

Cytosorbents Corp. Daily Stock Analysis
Stock Information
Open
5.50
Close
5.53
High
5.65
Low
5.49
Previous Close
5.50
Daily Price Gain
0.03
YTD High
8.82
YTD High Date
Jan 7, 2019
YTD Low
3.68
YTD Low Date
Aug 15, 2019
YTD Price Change
-2.32
YTD Gain
-29.55%
52 Week High
13.95
52 Week High Date
Sep 24, 2018
52 Week Low
3.68
52 Week Low Date
Aug 15, 2019
52 Week Price Change
-7.92
52 Week Gain
-58.88%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 28. 2017
5.75
Oct 12. 2017
6.20
10 Trading Days
7.85%
Link
LONG
Jan 3. 2018
6.60
Jan 23. 2018
7.49
13 Trading Days
13.54%
Link
LONG
May 11. 2018
8.05
Jun 11. 2018
11.19
20 Trading Days
39.03%
Link
LONG
Aug 17. 2018
11.55
Sep 11. 2018
13.70
16 Trading Days
18.57%
Link
Company Information
Stock Symbol
CTSO
Exchange
NasdaqCM
Company URL
http://www.cytosorbents.com
Company Phone
973-329-8885
CEO
Phillip P. Chan
Headquarters
New Jersey
Business Address
7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION, NJ 08852
Sector
Equity
Industry Category
Health Services
Industry Group
Medical Laboratories & Research
CIK
0001175151
About

CytoSorbents Corp. is a critical care immunotherapy company, which engages in blood purification to control deadly inflammation in critically-ill and cardiac surgery patients. Its products include cytosorb, contrastsorb, vetresq, hemodefend, and drugsorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.

Description

CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. The company also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. In addition, it is developing CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. Further, CytoSorbents Corporation is developing BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. CytoSorbents Corporation was founded in 1997 and is headquartered in Monmouth Junction, New Jersey.